Search for content, post, videos

Devyser to list its shares on Nasdaq First North Growth Market

Fredrik Alpsten

Devyser Diagnostics has announced its intention to launch an initial public offering of its shares and to list its shares on Nasdaq First North Premier Growth Market.

The offering is expected to consist of both new shares issued by Devyser and of existing shares in the company. Nasdaq has announced that the company meets the listing requirements.

“I am very pleased to announce the intended listing of Devyser on Nasdaq First North Premier Growth Market. The plans have generated a great deal of interest, both from new investors and existing owners. The listing is a milestone for Devyser and a logical next step in our successful and so far profitable growth journey. The Company has historically shown good profitability, but in 2020 took Devyser and active and conscious decision to invest in market and sales efforts to increase the growth rate. The funds provided by the planned share issue will enable continued investments in our international expansion and conversion of existing distributor markets into direct sales markets. The capital will furthermore enable continued successful product development while also providing flexibility for potential acquisitions that can accelerate the company’s growth. Increased marketing efforts in selected markets paired with a clear focus on direct sales and a stronger organization makes us well positioned to accelerate the already high sales growth even further. I am really looking forward to gaining new shareholders who will be able to take part in Devyser’s exciting growth journey,” says Fredrik Alpsten, CEO of Devyser.


Devyser develops, manufactures and sells kits for genetic testing in routine diagnostics to laboratories. The products are used for complex DNA testing in the areas of hereditary diseases, oncology and post-transplantation monitoring in order to enable diagnosis of a large number of genetic diseases, target cancer treatment, and follow-up transplant patients.

An important step

Devyser’s Board of Directors and company management, believe that the offering and the listing of Devyser is a logical and important step in the company’s development. The main focus for Devyser’s strategy is to continue to conduct sales of the current products on existing markets, convert selected existing markets from distributor sales to direct sales, expand to new geographic markets, as well as develop and launch new products. A listing will broaden the company’s shareholder base and provide access to the Swedish and international capital markets, which is believed will promote the company’s continued growth and development. The company also believes that a listing of the company’s shares on Nasdaq First North Premier Growth Market will increase knowledge about the company and strengthen the company’s brand.

Photo of Fredrik Alpsten: Devyser